The BRCA1-associated RING domain protein BARD1 acts with BRCA1 in double-strand break repair and ubiquitination. BARD1 plays a role as mediator of apoptosis by binding to and stabilizing p53, and BARD1-repressed cells are resistant to apoptosis. We therefore investigated the mechanism by which BARD1 induces p53 stability and apoptosis. The apoptotic activity of p53 is regulated by phosphorylation. We demonstrate that BARD1 binds to unphosphorylated and serine-15 phosphorylated forms of p53 in several cell types and that the region required for binding comprises the region sufficient for apoptosis induction. In addition, BARD1 binds to Ku-70, the regulatory subunit of DNA-PK, suggesting that the mechanism of p53-induced apoptosis requires BARD1 for the phosphorylation of p53. Upregulation of BARD1 alone is sufficient for stabilization of p53 and phosphorylation on serine-15, as shown in nonmalignant epithelial cells and ovarian cancer cells, NuTu-19, which are defective in apoptosis induction and express aberrant splice variants of BARD1. Stabilization and phosphorylation of p53 in NuTu-19 cells, as well as apoptosis, can be induced by the exogenous expression of wild-type BARD1, suggesting that BARD1, by binding to the kinase and its substrate, catalyses p53 phosphorylation.
Introduction
Apoptosis is an important means of eliminating dangerously damaged cells. Cancer cells have developed strategies to escape apoptosis and consequently become resistant to apoptosis inducing treatments. Along this line, the tumor suppressor p53, a key element in the apoptosis response pathway, is mutated in more than 50% of tumors. Several signaling pathways converge on the activation of p53, which leads either to cell cycle arrest and DNA repair or senescence, or apoptosis (Levine, 1997) . P53 activation and stabilization depend on its phosphorylation at multiple sites, by a number of kinases (Meek, 1994; Milczarek et al., 1997) . Phosphorylation at serines 6 and 9 by casein kinase 1-delta and casein kinase 1-epsilon occurs both in vitro and in vivo (Knippschild et al., 1997; Kohn, 1999) , the checkpoint kinases Chk1 and Chk2 phosphorylation at serine 20 enhances its tetramerization, stability, and activity Hirao et al., 2000) . Phosphorylation of p53 at serine-392 is observed in vitro by CDK-activating kinase (CAK) (Lu et al., 1997) and in vivo (Hao et al., 1996; Lu et al., 1997) , but is altered in human tumors. Serine-392 phosphorylation has been reported to influence the growth suppressor function, DNA binding, and transcription activation of p53 (Hao et al., 1996; Lohrum and Scheidtmann, 1996; Lu et al., 1997; Kohn, 1999) . Phosphorylation of p53 at serine-46 is important for regulating its ability to induce apoptosis (Oda et al., 2000) . However, the rapid response to DNA damage is induced by phosphorylation of p53 at serines 15, 20, and 37 and leads to reduced interaction of p53 with its negative regulator, oncoprotein MDM2 (Shieh et al., 1997) .
Known kinases for the DNA damage response are ATM, ATR, and DNA-PK, which can phosphorylate p53 at serines 15 and 37 (Shieh et al., 1997; Tibbetts et al., 1999) . These phosphorylation events impair the ability of MDM2 to bind p53, promoting both the accumulation and functional activation of p53 in response to DNA damage (Shieh et al., 1997; Tibbetts et al., 1999) . MDM2 acts as inhibitor of p53 function by targeting it for ubiquitination and proteasomal degradation (Honda et al., 1997; Chehab et al., 1999) .
The tumor suppressor BRCA1 Associated Ring Domain protein (BARD1) can act as a mediator between genotoxic stress and apoptosis by binding to and stabilizing p53 (Irminger-Finger et al., 2001; Irminger-Finger and Leung, 2002) . BARD1 is the major protein-binding partner of BRCA1 (Wu et al., 1996) and the BARD1/BRCA1 heterodimer has functions in DNA repair (Jin et al., 1997; Scully et al., 1997) and ubiquitination (Baer and Ludwig, 2002) . Both proteins are homologous within their RING domains and two BRCT domains. The BRCT domains of BRCA1 have recently been characterized as modules for kinase and target interaction (Manke et al., 2003; Yu et al., 2003) and a role of BARD1-BRCA1 complexes in signaling from DNA damage to p53 phosphorylation has been described recently (Fabbro et al., 2004) .
The repression of BARD1 expression in vitro results in genomic instability and cellular changes suggestive of a premalignant phenotype (Irminger-Finger et al., 1998) and resistance to apoptosis (Irminger-Finger et al., 2001) . Similarly, BARD1, as well as BRCA1, knockout cells exhibit high levels of genomic instability (Joukov et al., 2001; Ludwig et al., 2001; McCarthy et al., 2003) . However, excess of BARD1 over BRCA1 results in apoptosis independently of BRCA1 (Irminger-Finger et al., 2001) . Interestingly, the expression of BARD1, but not BRCA1, is hormonally controlled in uterine tissue (Irminger-Finger et al., 1998) , suggesting a role in tissue homeostasis. Further evidence for a role of BARD1 in tumor suppression is presented by BARD1 mutations found in breast, ovarian, and most intriguingly in endometrial tumors (Thai et al., 1998; Hashizume et al., 2001; Ghimenti et al., 2002; Ishitobi et al., 2003) . In contrast, BRCA1 mutations have not been found in uterine cancers, supporting a BRCA1-independent role of BARD1 in tumor suppression by apoptosis induction (Irminger-Finger and Leung, 2002) .
To further elucidate the mechanism by which BARD1 induces apoptosis, we investigated its possible function in the regulation of p53 phosphorylation required for apoptosis (Lakin and Jackson, 1999) .
Here we report that BARD1 is involved in p53 ser15 phosphorylation and BARD1 overexpression is sufficient for this phosphorylation. We identified a cancer cell line which is resistant to apoptosis and deficient in p53 ser15 phosphorylation in response to genotoxic stress. Indeed, BARD1 is mutated and deleted in this cell line and exogenous expression can restore p53 ser15 phosphorylation and apoptosis.
Results
Given the role of BARD1 in p53 stabilization, we investigated its expression in relation to p53 in various cell types. In nonmalignant mammary gland cells, TAC-2, treatment with the apoptosis-inducing drug doxorubicin resulted in the upregulation of BARD1 and accumulation of the p53 protein, as shown previously (Irminger-Finger et al., 2001) . Simultaneously to the increase of BARD1 and p53 protein levels upon genotoxic stress, the accumulation of phosphorylated p53 ser15 was observed when phospho-epitope-specific antibodies against phospho-p53 ser15 were used on Western blots (Figure 1a ). This is consistent with the reported stabilization of p53 by phosphorylation upon stress induction (Shieh et al., 1997) . Phosphorylation of serines 15, 20, and 37 is essential for p53 function during apoptosis (Shieh et al., 1997; Tibbetts et al., 1999) . Since serine 15, but not serines 20 and 37, is conserved between human, mouse, and rat p53, we determined whether this site was implicated in the resistance to apoptosis in cancer cells. We first compared the effect of doxorubicin treatment applied to TAC-2 cells and to highly malignant rat ovarian cancer cells, NuTu-19 (Rose et al., 1996) . NuTu-19 lack the full-length BARD1 protein and showed only a slight upregulation of p53, as compared to TAC-2 cells (Figure 1b) (Figure 1c ).
These data indicate that upregulation of BARD1 protein is sufficient for p53 upregulation and phosphorylation, suggesting that the function of BARD1 in p53 stabilization involves phosphorylation of p53 at the key residue serine-15 and that increased BARD1 protein levels can induce this post-translational modification.
To investigate whether BARD1 and p53 or phosphop53 physically interact, we used HEK 293T cells transfected with a cDNA expression vector of a BARD1-EGFP fusion construct expressed from the CMV promoter . Immunofluorescence microscopy was performed to visualize BARD1-EGFP, p53, and phospho-p53 ser15 with specific antibodies. When antibodies recognizing total p53 were used, we observed that all cells expressed p53 independently of BARD1-EGFP expression, whereas some accumulation of p53 in nuclear dots was correlated with BARD1-EGFP expression ( Figure 2a ). Using p53 antibodies specific for phospho-serine-15, no staining was observed in untransfected HEK 293T cells, while phospho-p53 was expressed in BARD1-EGFP-positive cells, and BARD1-EGFP and phospho-p53 ser15 co-localized in nuclear dots (Figure 2a We have previously shown that BARD1 binds to p53 in co-immunoprecipitation assays (Irminger-Finger et al., 2001) . To test BARD1 binding to phospho-p53, immunoprecipitation experiments were performed with cell extracts from HEK 293T, TAC-2, and NuTu-19 cells, using a C-terminal BARD1 antibody ( Figure 3a) . To obtain increased protein levels of BARD1 and p53, HEK 293T and NuTu-19 cells were transduced with BARD1-expressing lentiviral vector, and TAC-2 cells were treated with doxorubicin. To quantify the transduction efficiency, control transductions were performed using a GFP-expressing lentiviral vector. As shown previously (Irminger-Finger et al., 2001) , the increase of BARD1 was associated with the increase of p53 expression as compared to control transduction. Moreover, p53 and phospho p53 ser-15 levels were elevated in doxorubicin-treated TAC-2 cells and in BARD1-transduced HEK 293T and NuTu-19 cells. BARD1 antibodies co-immunoprecipitated p53 and phospho p53
ser-15 in all cell types. Phospho-p53 ser-15 was co- immunoprecipitated with BARD1 as efficiently as p53, albeit the amounts of p53 and phospho-p53 ser-15 were reduced in NuTu-19 as compared to TAC-2 and HEK 293T cells. These results indicate that BARD1 interacts with p53 and with phospho-p53 ser-15 in different cell types and cells from different species.
To further investigate the specificity of BARD1-dependent p53 ser15 phosphorylation, we tested the mutated forms of p53. Cotransfection assays were performed in p53-deficient human prostate cancer cells PC3 (Honda et al., 2002) . No p53 can be detected in PC3 cells without exogenous p53 expression, also ser15 and ser37 mutants do not express detectable amounts of protein after transfection. Triple mutant 33-81-315, however, is stable (Zacchi et al., 2002) . BARD1 cotransfection leads to an increase of wild-type p53 and of the triple mutant, but had no effect on p53 mutated at ser15 and ser37 ( Figure 3b ).
The interaction of BARD1 and p53 was also tested with BARD1-EGFP fusion constructs, using antibodies against p53 to co-immunoprecipitate BARD1-EGFP, which was assayed with anti-EGFP antibodies on Western blots (Figure 3c ). To determine the specific region of BARD1 required for this interaction, BARD1-EGFP deletion constructs were used in transfection assays followed by immunprecipitations with anti-p53 antibodies. Interestingly, all deletion constructs coimmunoprecipitated with anti-p53 except RING-EGFP, which represents the amino-terminal 89 amino acids of BARD1 (Figure 3c, d ). The minimal region required for binding to p53 was deletion construct ANK-EGFP, which was previously identified as the minimal region sufficient for apoptosis induction . This finding suggests that the molecular pathway of BARD1 signaling towards apoptosis is based on its role in p53 stabilization by phosphorylation.
Since p53 phosphorylation on serine 15 can be induced by overexpression of BARD1, it was tempting to speculate that BARD1 might act as a mediator between p53 and its specific kinase. Phosphorylation of p53 ser-15 and p53 ser-37 is required for p53 stabilization and for p53-dependent response to genotoxic stress (Shieh et al., 1997; Tibbetts et al., 1999; Jack et al., 2004) . A role of BARD1-BRCA1 complexes in phosphorylation of p53 ser-15 in an ATM/ATR pathway has been described recently (Fabbro et al., 2004) . We suspected that DNA-PK kinase might be responsible for p53 ser-15 phosphorylation in a BARD1-dependent pathway, since DNA-PK can phosphorylate p53 ser-15 upon genotoxic stress (Woo et al., 1998 (Woo et al., , 2002 and DNA-PK and Ku-70, the active subunit of DNA-PK, are upregulated in ATM/ATR-dependent stress response Shangary et al., 2000) . Most recently, it was found that Ku-70 mutation partially suppresses the homologous-repair defects of BARD1 disruption (Stark et al., 2004) , suggesting that both act in a common pathway.
We performed co-immunoprecipitation assays with anti-p53 antibodies, anti-Ku-70, the active subunit of DNA-PK, or anti-BARD1 antibodies to investigate the interactions between DNA-PK, p53, and BARD1 (Figure 4a ). Immunoprecipitation assays, when performed on lysates from HEK 293T cells, or HEK 293T cells transduced with BARD1-EGFP, revealed that BARD1 and p53 were co-immunoprecipitated with Ku-70. When anti-p53 antibodies were used to precipitate p53 or interacting proteins, p53 immunoprecipitation was nearly 100%, as was BARD1 co-immunoprecipitation with anti-Ku-70 antibodies (Figure 4a ).
We were interested whether NuTu-19 cells expressed Ku-70 and immunoprecipitation experiments were performed with untransfected and BARD1-transfected NuTu-19 cells (Figure 4b ). Only exogenous BARD1 could accumulate detectable amounts of Ku-70 in immunoprecipitation. No precipitation was observed when BARD1 antibodies were omitted.
As further evidence for the implication of DNA-PK, a member of the phosphoinositide 3-kinase related kinase (PIKK) family, in phosphorylation of p53 and interaction with BARD1, we treated cells with caffeine and doxorubicin. Caffeine is a well-known inhibitor of PIKK kinase activity and as a result can effectively inhibit the phosphorylation of p53 ser-15 . Doxorubicin on the other hand induces genotoxic stress on cells, consequently resulting in phosphorylation of p53 on the same residues inhibited by caffeine. After treatment of HEK 293T cells with 50 mM caffeine alone, we observed a slight elevation in p53 levels as compared to untreated cells; however, there was no change in the phospho-p53 levels (Figure 4c ). Doxorubicin treatment induces the expression of both p53 and BARD1, as described previously (Irminger-Finger et al., 2001; Jefford et al., 2004) . Since HEK 293T cells have constitutive p53 expression, no significant changes in p53 levels with or without genotoxic stress were observed. We did not observe substantial increase in phospho-p53 protein levels co-immunoprecipitating with BARD1 when treated with caffeine, but when treated with doxorubicin. The combined treatment with caffeine and doxorubicin resulted in decreased phosphop53 levels in both the supernatant and pellet fractions of the BARD1 immunocomplexes (Figure 4c ). This result provides further evidence that p53 is phosphorylated by a PIKK family member and that this reaction might be catalysed by the presence of BARD1, since BARD1 immunocomplexes contain both phosphorylated and unphosphorylated species of p53. The same immunoprecipitation extracts were probed with anti-ATM antibodies and no binding of ATM to BARD1 could be observed (Figure 4c ), thus supporting that DNA-PK rather than ATM is responsible for BARD1-dependent p53 ser-15 phosphorylation. While p53 phosphorylation was induced in several cell types by exogenous expression of BARD1, this effect was most striking in malignant ovarian cancer cells NuTu-19. NuTu-19 cells were generated by continuous in vitro culture of ovarian epithelial cells leading to spontaneous malignant transformation (Rose et al., 1996) . These cells lack full-length BARD1 protein (Figure 1b, c) . Cloning and sequencing of the BARD1 mRNAs expressed in NuTu-19 cells revealed that none of the cDNAs encoded a full-length BARD1 gene (Figure 5a, c, d ). The cDNA corresponding to the 2.2 kb BARD1 induces apoptosis A Feki et al wild-type BARD1 transcript contained point mutations leading to a premature translation stop at position 1786 between the ankyrin repeats (ANK) and the BRCT domains ( Figure 5a ). A smaller 2 kb fragment was due to deletion of exons 2 and 3. This mRNA species, herein designated BARD1g, was similar to the testis-specific mRNA BARD1b . This finding was corroborated by Western blots performed with three different previously characterized anti-BARD1 antibodies , which showed that full-length BARD1 protein is absent in NuTu-19 cells (Figure 5b) . HEK 293T expressed a 94-kDa protein, detectable with N-terminal antibodies H-300 and PVC, directed against the region adjacent to the RING finger, and JH3, directed against the regions between ANK and BRCT. None of the antibodies tested recognized a protein fragment corresponding to the molecular weight of fulllength BARD1 in NuTu-19 cell extracts. Consistently, the most abundant transcript of BARD1 in NuTu-19 cells was an 800 bp RT-PCR product, a novel splice variant, hitherto named BARD1d. BARD1d lacks exons 2-7, which include regions coding for the RING finger and the ankyrin repeats (Figure 5c, d) . Therefore, NuTu-19 cells do not express full-length BARD1 molecules and none of the BARD1 transcripts encode ANK repeats and the region between ANK and BRCT. Interestingly, nucleotides 1618-1641 represent an inverted repeat of region 804-826, which could act as antisense to abrogate the translation of BARD1, but not BARD1d transcripts. Mutations and deletions in the BARD1 coding region were in strong contrast to the status of p53. Cloning and sequencing of the p53 cDNA from NuTu-19 cells revealed two polymorphisms, S66P and L192F, within the less conserved domains of p53, but no mutations that predict structural changes of the encoded protein.
We had evaluated the apoptotic activity of NuTu-19 cells after treatment with UV or doxorubicin. NuTu-19 cells show little response to apoptosis-inducing drugs as measured by FACS and TUNEL assays. Doxorubicin treatment resulted in no significant increase of apoptotic cells as observed after TUNEL or 7AAD staining and flow cytometry analysis (Figure 6a ). However, when we overexpressed wild-type BARD1 by (Figure 6c ).
This experiment proved that expression of wild-type BARD1 could reverse apoptosis resistance in cells lacking full-length BARD1. In nonmalignant cells with endogenous wild-type BARD1, overexpression of exogenous BARD1 is sufficient to stabilize p53 and to induce p53 ser-15 phosphorylation. In BARD1-deficient NuTu-19 cells, phosphorylation of p53 cannot be induced by apoptosis-inducing drugs, but by the exogenous expression of wild BARD1, without other stress signals, suggesting that BARD1 facilitates the phosphorylation of p53 by binding to p53 and Ku-70, the subunit of DNA-PK, and that this is sufficient and required for apoptosis induction.
Discussion
In the present study we demonstrate that BARD1 plays a critical role in phosphorylation of p53, which is required for its apoptotic function. Several kinases involved in p53 activation have been reported (Lu et al., 1997; Shieh et al., 1997 Shieh et al., , 1999 Tibbetts et al., 1999; Hirao et al., 2000) and ATM/ATR-dependent phosphorylation of p53 ser-15 , implicating BRCA1-BARD1 complexes, has been described very recently (Fabbro et al., 2004) .
It was shown before that BRCT domains, a protein motif also present in BARD1 and BRCA1, have phospho-epitope-binding capacities (Rodriguez et al., 2003) . A phospho-epitope-binding function was reported specifically for BRCT domains of BRCA1. BRCT domains are present in many other repair proteins and seem to facilitate physical interactions among proteins involved in the cellular response to DNA damage check point control and DNA repair (Bork et al., 1997; Callebaut and Mornon, 1997) . It is speculated that BRCT domains are important modules for tumor suppressor functions, supported by cancerassociated mutations within the BRCT domain of BRCA1 (Williams et al., 2001) .
BARD1 contains tandem BRCT motifs, it has tumor suppressor functions (Irminger-Finger and Leung, 2002) , and it binds and stabilizes p53 (Irminger-Finger et al., 2001) which is suggestive of a role in a pathway of p53 phosphorylation. Here we show that, indeed, BARD1 binds to p53 and phospho-p53 and, secondly, BARD1 interacts with the DNA-PK subunit, Ku-70, but not ATM. The region sufficient for p53 interaction and apoptosis induction comprises ANK, the region between ANK and BRCT, and part of the BRCT domains. It is possible that the BRCT domains are binding to the kinase and that its target is binding to the adjacent region.
Ku-70 is abundantly expressed in HEK 293T cells, as is p53, as compared to BARD1. Nevertheless, overexpression of BARD1, without an additional stimulus through DNA damage, causes p53 phosphorylation in HEK 293T cells and NuTu-19 cells, suggesting that BARD1 is an essential and limiting partner for the formation of the p53-DNA-PK complex. Consistent with this view, BARD1 co-localizes with phospho-p53 in distinct nuclear dots (Figure 5b ). Since overexpression of BARD1 is sufficient for p53 ser15 phosphorylation, binding of BARD1 to the kinase and its target catalyses p53 phosphorylation.
Supporting this view, several cancer-associated missense mutations (Thai et al., 1998; Ghimenti et al., 2002; Ishitobi et al., 2003) , map to the region defined sufficient for p53 binding and apoptosis induction, and it is deleted or mutated in the NuTu-19 cells, described here.
It is likely that BARD1 deficiencies are frequent in cancer cells that have wild-type p53 but are resistant to apoptosis, and significant changes in BARD1 expression have been found associated with malignancies (Pomeroy et al., 2002; Iyengar et al., 2003; Schafer et al., 2003; Zuco et al., 2003) . The NuTu-19 ovarian cancer cells, to some extent, are a model of ovarian cancer, which suggests that BARD1 is a key target for mutations leading to carcinogenesis. NuTu-19 cells are derived from a spontaneous transformation of continuously cultured ovarian epithelial cells (Rose et al., 1996) , suggesting that few genetic modifications led to the phenotype of resistance to undergo apoptosis. This process mimics the in vivo situation, as it has been hypothesized that proliferation associated with ovarian repair contributes to the risk of ovarian cancer in humans (Fathalla, 1972) . We speculated and confirmed here that one of the critical mutations for malignant transformation involves the tumor suppressor BARD1.
Indeed, rat ovarian cancer cells, NuTu-19, have applied several strategies to eliminate the expression of functional BARD1: mutations leading to a truncated form of the protein, differential splicing leading to the deletion of essential parts of the protein, and possibly repression of the partially active forms of the protein by expression of a short inverse repeat sequence that could function as antisense RNA in transcriptional repression of wild-type forms of BARD1. These mechanisms of inhibition of BARD1 function are consistent with the hypothesis that BARD1 is an essential tumor suppressor, critical for apoptosis induction upon damage, by stabilizing p53 (Irminger-Finger et al., 2001) . BARD1 binding to p53 could also influence p53 stability by inhibiting its ubiquitination and/or its binding to MDM2 (Meek, 1994; Honda et al., 1997; Milczarek et al., 1997) .
Consistently, no phosphorylation of p53 is observed in NuTu-19 cells in the absence of exogenous expression of wild-type BARD1. Co-immunoprecipitation experiments suggest that BARD1 binds both the kinase and its respective target p53 and catalyses its phosphorylation. This could be explained mechanistically by a higher affinity between BARD1 and Ku-70 and between BARD1 and p53 than between p53 and Ku-70. Our data support this view, since co-immunoprecipitations of BARD1 and p53 or BARD1 and Ku-70 are more efficient than co-immunoprecipitations of p53 and Ku-70. In addition, BARD1 protein levels are considerably lower in the cell than either p53 or Ku-70, therefore BARD1 can be regarded as the critical and limiting factor in the formation of the p53/Ku-70 complexes. Furthermore, the overexpression of BARD1 alone without induction of the DNA damage pathway is sufficient for p53 phosphorylation and supports the view that BARD1 catalyses p53 phosphorylation by DNA-PK.
Materials and methods

Cell cultures
The HEK 293T cell line, as well as HeLa cells, were obtained from the ATCC. NuTu-19 cells (Rose et al., 1996) were a generous gift from Dr Attila Major, Geneva, PC3, human prostate cancer cells, were obtained from Dr Timothy MacDonnell, Houston. All cell lines were cultured in 10 cm plastic tissue culture dishes (NUNC, Roskilde, Denmark) and incubated at 371C in humidified air containing 5% CO2. Adherent subcultures were detached from culture dishes using a solution of Trypsin/EDTA in HBSS without Ca 2 þ or Mg 2 þ . Subconfluent cell cultures were passaged regularly at 1 : 10 dilution approximately twice a week. All cell culture media, solutions, buffers, and antibiotics were purchased from BARD1 induces apoptosis A Feki et al GIBCO (Invitrogen AG, Basel, Switzerland) . HEK 293T cells were pretreated for 1 h with 50 mM caffeine, after which they were either treated with doxorubicin (50 mg/ml) or left untreated as described previously (Irminger-Finger et al., 1998) .
Western blotting
For Western blots, protein extracts from cell cultures were prepared in standard lysis buffer (150 mM NaCl, 0.1% SDS, 50 mM Tris (pH 8.0)). Equal concentrations of all whole cell extracts per gel were loaded onto SDS-PAA gels according to Laemmli's protocol and were transferred to polyvinylidene fluoride (PVDF) membranes. Filters were blocked for 1 h in PBS containing 5% non-fat milk and then incubated at room temperature for 2 h with a polyclonal BARD1 (IrmingerFinger et al., 1998), p53 and P-p53 (Santa Cruz) antibodies. After washing, membranes were incubated with horseradish peroxidase-conjugated secondary antibody and the resulting complexes were visualized by an enhanced chemiluminescence (ECL) system (Boehringer).
Immunoprecipitation
Immunoprecipitation was performed by homogenizing cell samples in 100 ml (100-150 mg total protein) RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% NaDOC, 0.1 SDS, 50 mM Tris (pH 8.0), and 2 mM EDTA (pH 8.0)). Cells extracts were incubated with p53 antibody (FL-393 Santa Cruz), or GFP antibody (Torrey Pines Biolabs, Inc) in a 1 : 200 dilution over night, followed by incubation with sepharose-bound protein G for 3 h. Extracts were centrifuged, and pellets were washed twice with RIPA buffer and re-suspended in 100 ml RIPA buffer. In all, 25 ml of supernatant and pellet fractions was analysed by Western blotting. Total protein content in supernatant and pellet fractions was compared by fast green staining after protein transfer and was 90-10% at least. Antibody reactive bands were visualized, scanned, and quantified using Imagequant.
Antibodies
The anti-BARD1 (H300), anti-p53 (FL-393), and antiphospho p53 ser15 antibodies (Cell Signaling 5284) were purchased from Santa Cruz. Anti-GFP (TP-401) was purchased from Chemokine (Torrey Pines Biolabs, Houston, TX, USA). WFS is a previously described anti-BARD1 antibody (Gautier et al., 2000) . Horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Santa Cruz and were compatible with Cruz Molecular Weight Markers (Santa Cruz, CA, USA).
RT-PCR
Total RNA was purified from NuTu-19 cells using Qiagen reagent. RNA was reverse transcribed using oligo-dT and superscript II (Life Technologies). RT products were subjected to PCR analysis using specific primers for rat BARD1 cDNA (covering BARD1 coding regions) and rat p53 (covering p53 coding regions). PCR cycles were: 941C for 15 min, 941C for 1 min, 561C for 1 min, 721C for 2 min 30 s for BARD1 and 1 min 30 s for p53 (35 Â ), then 721C for 10 min. Equal volumes of PCR products were analysed on 1% agarose gel.
Lentiviral vector production and transduction
The packaging constructs used in this study were the pCMVDR8.92 and the pCMVDR8.93 plasmids described previously (Dull et al., 1998) . The vesicular stomatitis virus G (VSV-G) envelop was the pM2DG plasmid (Zufferey et al., 1997) . The BARD1 coding sequence was cloned into the carrier pLOXEW plasmid (Zufferey et al., 1997) . The viral particles were produced using the usual transient transfection method (Zufferey et al., 1997) . The 293T cells (2.8 Â 10 6 cells in 10-cm tissue culture dishes) were co-transfected with either 10 mg of pLOXEW-BARD1 ires-GFP, 3.75 mg of pCMVDR8.92, 3.75 mg of pCMVDR8.93, and 2.5 mg of pM2DG, or 10 mg of pHR 0 -CMV-BARD1, 3.75 mg of pCMVDR8.92, 3.75 mg of pCMVDR8.93, and 2.5 mg of pM2DG.
After an overnight incubation in the presence of the precipitate, the culture medium (10 ml) was changed. Two days later, the supernatant was harvested, filtered through 0.45-mm pore-sized polyethersulfone membrane and subsequently 1 ml of each was added to NuTu-19 target cells in sixwell plates (10 4 cells/well). Vector particles were left on the cells for 3 days. Transduction efficiency was monitored using a GFP-expressing vector.
Plasmid constructions and transfection
Different BARD1 mutants fused with GFP, was described previously, were used. Briefly, the full-length mouse BARD1 cDNA (Irminger-Finger et al., 1998) was used to generate the deletion constructs in pcDNA3 behind a CMV promoter. The plasmid pEGFP-N1 (enhanced green fluorescent protein) was purchased from Clontech and was used to generate either the full-length BARD1-EGFP or BARD1 deletion-bearing mutants fused in-frame with the EGFP tag. The deletion-bearing constructs were the same as described . HEK293T cells were seeded in 10 cm petri dishes and transfected with 2 mg of DNA using the Effectene reagents from Qiagen. Cells were harvested 48 h post-transfection.
